

# COVID-19 Impact on Global Indolent Lymphoma Treatment Market Size, Status and Forecast 2020-2026

<https://marketpublishers.com/r/C919D0118CE5EN.html>

Date: September 2020

Pages: 92

Price: US\$ 3,900.00 (Single User License)

ID: C919D0118CE5EN

## Abstracts

This report focuses on the global Indolent Lymphoma Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Indolent Lymphoma Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study

Altor BioScience Corporation

Amgen Inc.

Astellas Pharma Inc.

Bayer AG

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Celgene Corporation

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Gilead Sciences, Inc.

Incyte Corporation

Infinity Pharmaceuticals, Inc.

Juno Therapeutics Inc.

MedImmune, LLC

Market segment by Type, the product can be split into

BI-836826

ALT-803

BMS-986016

CC-122

Others

Market segment by Application, split into

Hospital

Clinic

Others

Market segment by Regions/Countries, this report covers

North America

Europe

China

Japan

Southeast Asia

India

Central & South America

The study objectives of this report are:

To analyze global Indolent Lymphoma Treatment status, future forecast, growth opportunity, key market and key players.

To present the Indolent Lymphoma Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

To strategically profile the key players and comprehensively analyze their development plan and strategies.

To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Indolent Lymphoma Treatment are as follows:

History Year: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

## Contents

### 1 REPORT OVERVIEW

1.1 Study Scope

1.2 Key Market Segments

1.3 Players Covered: Ranking by Indolent Lymphoma Treatment Revenue

1.4 Market Analysis by Type

1.4.1 Global Indolent Lymphoma Treatment Market Size Growth Rate by Type: 2020 VS 2026

1.4.2 BI-836826

1.4.3 ALT-803

1.4.4 BMS-986016

1.4.5 CC-122

1.4.6 Others

1.5 Market by Application

1.5.1 Global Indolent Lymphoma Treatment Market Share by Application: 2020 VS 2026

1.5.2 Hospital

1.5.3 Clinic

1.5.4 Others

1.6 Coronavirus Disease 2019 (Covid-19): Indolent Lymphoma Treatment Industry Impact

1.6.1 How the Covid-19 is Affecting the Indolent Lymphoma Treatment Industry

1.6.1.1 Indolent Lymphoma Treatment Business Impact Assessment - Covid-19

1.6.1.2 Supply Chain Challenges

1.6.1.3 COVID-19's Impact On Crude Oil and Refined Products

1.6.2 Market Trends and Indolent Lymphoma Treatment Potential Opportunities in the COVID-19 Landscape

1.6.3 Measures / Proposal against Covid-19

1.6.3.1 Government Measures to Combat Covid-19 Impact

1.6.3.2 Proposal for Indolent Lymphoma Treatment Players to Combat Covid-19

Impact

1.7 Study Objectives

1.8 Years Considered

### 2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Indolent Lymphoma Treatment Market Perspective (2015-2026)

## 2.2 Indolent Lymphoma Treatment Growth Trends by Regions

2.2.1 Indolent Lymphoma Treatment Market Size by Regions: 2015 VS 2020 VS 2026

2.2.2 Indolent Lymphoma Treatment Historic Market Share by Regions (2015-2020)

2.2.3 Indolent Lymphoma Treatment Forecasted Market Size by Regions (2021-2026)

## 2.3 Industry Trends and Growth Strategy

2.3.1 Market Top Trends

2.3.2 Market Drivers

2.3.3 Market Challenges

2.3.4 Porter's Five Forces Analysis

2.3.5 Indolent Lymphoma Treatment Market Growth Strategy

2.3.6 Primary Interviews with Key Indolent Lymphoma Treatment Players (Opinion Leaders)

## **3 COMPETITION LANDSCAPE BY KEY PLAYERS**

### 3.1 Global Top Indolent Lymphoma Treatment Players by Market Size

3.1.1 Global Top Indolent Lymphoma Treatment Players by Revenue (2015-2020)

3.1.2 Global Indolent Lymphoma Treatment Revenue Market Share by Players (2015-2020)

3.1.3 Global Indolent Lymphoma Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

### 3.2 Global Indolent Lymphoma Treatment Market Concentration Ratio

3.2.1 Global Indolent Lymphoma Treatment Market Concentration Ratio (CR5 and HHI)

3.2.2 Global Top 10 and Top 5 Companies by Indolent Lymphoma Treatment Revenue in 2019

### 3.3 Indolent Lymphoma Treatment Key Players Head office and Area Served

### 3.4 Key Players Indolent Lymphoma Treatment Product Solution and Service

### 3.5 Date of Enter into Indolent Lymphoma Treatment Market

### 3.6 Mergers & Acquisitions, Expansion Plans

## **4 BREAKDOWN DATA BY TYPE (2015-2026)**

### 4.1 Global Indolent Lymphoma Treatment Historic Market Size by Type (2015-2020)

### 4.2 Global Indolent Lymphoma Treatment Forecasted Market Size by Type (2021-2026)

## **5 INDOLENT LYMPHOMA TREATMENT BREAKDOWN DATA BY APPLICATION (2015-2026)**

- 5.1 Global Indolent Lymphoma Treatment Market Size by Application (2015-2020)
- 5.2 Global Indolent Lymphoma Treatment Forecasted Market Size by Application (2021-2026)

## **6 NORTH AMERICA**

- 6.1 North America Indolent Lymphoma Treatment Market Size (2015-2020)
- 6.2 Indolent Lymphoma Treatment Key Players in North America (2019-2020)
- 6.3 North America Indolent Lymphoma Treatment Market Size by Type (2015-2020)
- 6.4 North America Indolent Lymphoma Treatment Market Size by Application (2015-2020)

## **7 EUROPE**

- 7.1 Europe Indolent Lymphoma Treatment Market Size (2015-2020)
- 7.2 Indolent Lymphoma Treatment Key Players in Europe (2019-2020)
- 7.3 Europe Indolent Lymphoma Treatment Market Size by Type (2015-2020)
- 7.4 Europe Indolent Lymphoma Treatment Market Size by Application (2015-2020)

## **8 CHINA**

- 8.1 China Indolent Lymphoma Treatment Market Size (2015-2020)
- 8.2 Indolent Lymphoma Treatment Key Players in China (2019-2020)
- 8.3 China Indolent Lymphoma Treatment Market Size by Type (2015-2020)
- 8.4 China Indolent Lymphoma Treatment Market Size by Application (2015-2020)

## **9 JAPAN**

- 9.1 Japan Indolent Lymphoma Treatment Market Size (2015-2020)
- 9.2 Indolent Lymphoma Treatment Key Players in Japan (2019-2020)
- 9.3 Japan Indolent Lymphoma Treatment Market Size by Type (2015-2020)
- 9.4 Japan Indolent Lymphoma Treatment Market Size by Application (2015-2020)

## **10 SOUTHEAST ASIA**

- 10.1 Southeast Asia Indolent Lymphoma Treatment Market Size (2015-2020)
- 10.2 Indolent Lymphoma Treatment Key Players in Southeast Asia (2019-2020)
- 10.3 Southeast Asia Indolent Lymphoma Treatment Market Size by Type (2015-2020)
- 10.4 Southeast Asia Indolent Lymphoma Treatment Market Size by Application

(2015-2020)

## **11 INDIA**

- 11.1 India Indolent Lymphoma Treatment Market Size (2015-2020)
- 11.2 Indolent Lymphoma Treatment Key Players in India (2019-2020)
- 11.3 India Indolent Lymphoma Treatment Market Size by Type (2015-2020)
- 11.4 India Indolent Lymphoma Treatment Market Size by Application (2015-2020)

## **12 CENTRAL & SOUTH AMERICA**

- 12.1 Central & South America Indolent Lymphoma Treatment Market Size (2015-2020)
- 12.2 Indolent Lymphoma Treatment Key Players in Central & South America (2019-2020)
- 12.3 Central & South America Indolent Lymphoma Treatment Market Size by Type (2015-2020)
- 12.4 Central & South America Indolent Lymphoma Treatment Market Size by Application (2015-2020)

## **13 KEY PLAYERS PROFILES**

- 13.1 Altor BioScience Corporation
  - 13.1.1 Altor BioScience Corporation Company Details
  - 13.1.2 Altor BioScience Corporation Business Overview and Its Total Revenue
  - 13.1.3 Altor BioScience Corporation Indolent Lymphoma Treatment Introduction
  - 13.1.4 Altor BioScience Corporation Revenue in Indolent Lymphoma Treatment Business (2015-2020))
  - 13.1.5 Altor BioScience Corporation Recent Development
- 13.2 Amgen Inc.
  - 13.2.1 Amgen Inc. Company Details
  - 13.2.2 Amgen Inc. Business Overview and Its Total Revenue
  - 13.2.3 Amgen Inc. Indolent Lymphoma Treatment Introduction
  - 13.2.4 Amgen Inc. Revenue in Indolent Lymphoma Treatment Business (2015-2020)
  - 13.2.5 Amgen Inc. Recent Development
- 13.3 Astellas Pharma Inc.
  - 13.3.1 Astellas Pharma Inc. Company Details
  - 13.3.2 Astellas Pharma Inc. Business Overview and Its Total Revenue
  - 13.3.3 Astellas Pharma Inc. Indolent Lymphoma Treatment Introduction
  - 13.3.4 Astellas Pharma Inc. Revenue in Indolent Lymphoma Treatment Business

(2015-2020)

13.3.5 Astellas Pharma Inc. Recent Development

13.4 Bayer AG

13.4.1 Bayer AG Company Details

13.4.2 Bayer AG Business Overview and Its Total Revenue

13.4.3 Bayer AG Indolent Lymphoma Treatment Introduction

13.4.4 Bayer AG Revenue in Indolent Lymphoma Treatment Business (2015-2020)

13.4.5 Bayer AG Recent Development

13.5 Boehringer Ingelheim GmbH

13.5.1 Boehringer Ingelheim GmbH Company Details

13.5.2 Boehringer Ingelheim GmbH Business Overview and Its Total Revenue

13.5.3 Boehringer Ingelheim GmbH Indolent Lymphoma Treatment Introduction

13.5.4 Boehringer Ingelheim GmbH Revenue in Indolent Lymphoma Treatment Business (2015-2020)

13.5.5 Boehringer Ingelheim GmbH Recent Development

13.6 Bristol-Myers Squibb Company

13.6.1 Bristol-Myers Squibb Company Company Details

13.6.2 Bristol-Myers Squibb Company Business Overview and Its Total Revenue

13.6.3 Bristol-Myers Squibb Company Indolent Lymphoma Treatment Introduction

13.6.4 Bristol-Myers Squibb Company Revenue in Indolent Lymphoma Treatment Business (2015-2020)

13.6.5 Bristol-Myers Squibb Company Recent Development

13.7 Celgene Corporation

13.7.1 Celgene Corporation Company Details

13.7.2 Celgene Corporation Business Overview and Its Total Revenue

13.7.3 Celgene Corporation Indolent Lymphoma Treatment Introduction

13.7.4 Celgene Corporation Revenue in Indolent Lymphoma Treatment Business (2015-2020)

13.7.5 Celgene Corporation Recent Development

13.8 Eli Lilly and Company

13.8.1 Eli Lilly and Company Company Details

13.8.2 Eli Lilly and Company Business Overview and Its Total Revenue

13.8.3 Eli Lilly and Company Indolent Lymphoma Treatment Introduction

13.8.4 Eli Lilly and Company Revenue in Indolent Lymphoma Treatment Business (2015-2020)

13.8.5 Eli Lilly and Company Recent Development

13.9 F. Hoffmann-La Roche Ltd.

13.9.1 F. Hoffmann-La Roche Ltd. Company Details

13.9.2 F. Hoffmann-La Roche Ltd. Business Overview and Its Total Revenue



- 13.9.3 F. Hoffmann-La Roche Ltd. Indolent Lymphoma Treatment Introduction
- 13.9.4 F. Hoffmann-La Roche Ltd. Revenue in Indolent Lymphoma Treatment Business (2015-2020)
- 13.9.5 F. Hoffmann-La Roche Ltd. Recent Development
- 13.10 Gilead Sciences, Inc.
  - 13.10.1 Gilead Sciences, Inc. Company Details
  - 13.10.2 Gilead Sciences, Inc. Business Overview and Its Total Revenue
  - 13.10.3 Gilead Sciences, Inc. Indolent Lymphoma Treatment Introduction
  - 13.10.4 Gilead Sciences, Inc. Revenue in Indolent Lymphoma Treatment Business (2015-2020)
  - 13.10.5 Gilead Sciences, Inc. Recent Development
- 13.11 Incyte Corporation
  - 10.11.1 Incyte Corporation Company Details
  - 10.11.2 Incyte Corporation Business Overview and Its Total Revenue
  - 10.11.3 Incyte Corporation Indolent Lymphoma Treatment Introduction
  - 10.11.4 Incyte Corporation Revenue in Indolent Lymphoma Treatment Business (2015-2020)
  - 10.11.5 Incyte Corporation Recent Development
- 13.12 Infinity Pharmaceuticals, Inc.
  - 10.12.1 Infinity Pharmaceuticals, Inc. Company Details
  - 10.12.2 Infinity Pharmaceuticals, Inc. Business Overview and Its Total Revenue
  - 10.12.3 Infinity Pharmaceuticals, Inc. Indolent Lymphoma Treatment Introduction
  - 10.12.4 Infinity Pharmaceuticals, Inc. Revenue in Indolent Lymphoma Treatment Business (2015-2020)
  - 10.12.5 Infinity Pharmaceuticals, Inc. Recent Development
- 13.13 Juno Therapeutics Inc.
  - 10.13.1 Juno Therapeutics Inc. Company Details
  - 10.13.2 Juno Therapeutics Inc. Business Overview and Its Total Revenue
  - 10.13.3 Juno Therapeutics Inc. Indolent Lymphoma Treatment Introduction
  - 10.13.4 Juno Therapeutics Inc. Revenue in Indolent Lymphoma Treatment Business (2015-2020)
  - 10.13.5 Juno Therapeutics Inc. Recent Development
- 13.14 MedImmune, LLC
  - 10.14.1 MedImmune, LLC Company Details
  - 10.14.2 MedImmune, LLC Business Overview and Its Total Revenue
  - 10.14.3 MedImmune, LLC Indolent Lymphoma Treatment Introduction
  - 10.14.4 MedImmune, LLC Revenue in Indolent Lymphoma Treatment Business (2015-2020)
  - 10.14.5 MedImmune, LLC Recent Development

## **14 ANALYST'S VIEWPOINTS/CONCLUSIONS**

## **15 APPENDIX**

### 15.1 Research Methodology

#### 15.1.1 Methodology/Research Approach

#### 15.1.2 Data Source

### 15.2 Disclaimer

### 15.3 Author Details

## List Of Tables

### LIST OF TABLES

Table 1. Indolent Lymphoma Treatment Key Market Segments

Table 2. Key Players Covered: Ranking by Indolent Lymphoma Treatment Revenue

Table 3. Ranking of Global Top Indolent Lymphoma Treatment Manufacturers by Revenue (US\$ Million) in 2019

Table 4. Global Indolent Lymphoma Treatment Market Size Growth Rate by Type (US\$ Million): 2020 VS 2026

Table 5. Key Players of BI-836826

Table 6. Key Players of ALT-803

Table 7. Key Players of BMS-986016

Table 8. Key Players of CC-122

Table 9. Key Players of Others

Table 10. COVID-19 Impact Global Market: (Four Indolent Lymphoma Treatment Market Size Forecast Scenarios)

Table 11. Opportunities and Trends for Indolent Lymphoma Treatment Players in the COVID-19 Landscape

Table 12. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis

Table 13. Key Regions/Countries Measures against Covid-19 Impact

Table 14. Proposal for Indolent Lymphoma Treatment Players to Combat Covid-19 Impact

Table 15. Global Indolent Lymphoma Treatment Market Size Growth by Application (US\$ Million): 2020 VS 2026

Table 16. Global Indolent Lymphoma Treatment Market Size by Regions (US\$ Million): 2020 VS 2026

Table 17. Global Indolent Lymphoma Treatment Market Size by Regions (2015-2020) (US\$ Million)

Table 18. Global Indolent Lymphoma Treatment Market Share by Regions (2015-2020)

Table 19. Global Indolent Lymphoma Treatment Forecasted Market Size by Regions (2021-2026) (US\$ Million)

Table 20. Global Indolent Lymphoma Treatment Market Share by Regions (2021-2026)

Table 21. Market Top Trends

Table 22. Key Drivers: Impact Analysis

Table 23. Key Challenges

Table 24. Indolent Lymphoma Treatment Market Growth Strategy

Table 25. Main Points Interviewed from Key Indolent Lymphoma Treatment Players

Table 26. Global Indolent Lymphoma Treatment Revenue by Players (2015-2020)

(Million US\$)

Table 27. Global Indolent Lymphoma Treatment Market Share by Players (2015-2020)

Table 28. Global Top Indolent Lymphoma Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Indolent Lymphoma Treatment as of 2019)

Table 29. Global Indolent Lymphoma Treatment by Players Market Concentration Ratio (CR5 and HHI)

Table 30. Key Players Headquarters and Area Served

Table 31. Key Players Indolent Lymphoma Treatment Product Solution and Service

Table 32. Date of Enter into Indolent Lymphoma Treatment Market

Table 33. Mergers & Acquisitions, Expansion Plans

Table 34. Global Indolent Lymphoma Treatment Market Size by Type (2015-2020)  
(Million US\$)

Table 35. Global Indolent Lymphoma Treatment Market Size Share by Type  
(2015-2020)

Table 36. Global Indolent Lymphoma Treatment Revenue Market Share by Type  
(2021-2026)

Table 37. Global Indolent Lymphoma Treatment Market Size Share by Application  
(2015-2020)

Table 38. Global Indolent Lymphoma Treatment Market Size by Application  
(2015-2020) (Million US\$)

Table 39. Global Indolent Lymphoma Treatment Market Size Share by Application  
(2021-2026)

Table 40. North America Key Players Indolent Lymphoma Treatment Revenue  
(2019-2020) (Million US\$)

Table 41. North America Key Players Indolent Lymphoma Treatment Market Share  
(2019-2020)

Table 42. North America Indolent Lymphoma Treatment Market Size by Type  
(2015-2020) (Million US\$)

Table 43. North America Indolent Lymphoma Treatment Market Share by Type  
(2015-2020)

Table 44. North America Indolent Lymphoma Treatment Market Size by Application  
(2015-2020) (Million US\$)

Table 45. North America Indolent Lymphoma Treatment Market Share by Application  
(2015-2020)

Table 46. Europe Key Players Indolent Lymphoma Treatment Revenue (2019-2020)  
(Million US\$)

Table 47. Europe Key Players Indolent Lymphoma Treatment Market Share  
(2019-2020)

Table 48. Europe Indolent Lymphoma Treatment Market Size by Type (2015-2020)

(Million US\$)

Table 49. Europe Indolent Lymphoma Treatment Market Share by Type (2015-2020)

Table 50. Europe Indolent Lymphoma Treatment Market Size by Application (2015-2020) (Million US\$)

Table 51. Europe Indolent Lymphoma Treatment Market Share by Application (2015-2020)

Table 52. China Key Players Indolent Lymphoma Treatment Revenue (2019-2020) (Million US\$)

Table 53. China Key Players Indolent Lymphoma Treatment Market Share (2019-2020)

Table 54. China Indolent Lymphoma Treatment Market Size by Type (2015-2020) (Million US\$)

Table 55. China Indolent Lymphoma Treatment Market Share by Type (2015-2020)

Table 56. China Indolent Lymphoma Treatment Market Size by Application (2015-2020) (Million US\$)

Table 57. China Indolent Lymphoma Treatment Market Share by Application (2015-2020)

Table 58. Japan Key Players Indolent Lymphoma Treatment Revenue (2019-2020) (Million US\$)

Table 59. Japan Key Players Indolent Lymphoma Treatment Market Share (2019-2020)

Table 60. Japan Indolent Lymphoma Treatment Market Size by Type (2015-2020) (Million US\$)

Table 61. Japan Indolent Lymphoma Treatment Market Share by Type (2015-2020)

Table 62. Japan Indolent Lymphoma Treatment Market Size by Application (2015-2020) (Million US\$)

Table 63. Japan Indolent Lymphoma Treatment Market Share by Application (2015-2020)

Table 64. Southeast Asia Key Players Indolent Lymphoma Treatment Revenue (2019-2020) (Million US\$)

Table 65. Southeast Asia Key Players Indolent Lymphoma Treatment Market Share (2019-2020)

Table 66. Southeast Asia Indolent Lymphoma Treatment Market Size by Type (2015-2020) (Million US\$)

Table 67. Southeast Asia Indolent Lymphoma Treatment Market Share by Type (2015-2020)

Table 68. Southeast Asia Indolent Lymphoma Treatment Market Size by Application (2015-2020) (Million US\$)

Table 69. Southeast Asia Indolent Lymphoma Treatment Market Share by Application (2015-2020)

Table 70. India Key Players Indolent Lymphoma Treatment Revenue (2019-2020)

(Million US\$)

Table 71. India Key Players Indolent Lymphoma Treatment Market Share (2019-2020)

Table 72. India Indolent Lymphoma Treatment Market Size by Type (2015-2020)

(Million US\$)

Table 73. India Indolent Lymphoma Treatment Market Share by Type (2015-2020)

Table 74. India Indolent Lymphoma Treatment Market Size by Application (2015-2020)

(Million US\$)

Table 75. India Indolent Lymphoma Treatment Market Share by Application

(2015-2020)

Table 76. Central & South America Key Players Indolent Lymphoma Treatment

Revenue (2019-2020) (Million US\$)

Table 77. Central & South America Key Players Indolent Lymphoma Treatment Market

Share (2019-2020)

Table 78. Central & South America Indolent Lymphoma Treatment Market Size by Type

(2015-2020) (Million US\$)

Table 79. Central & South America Indolent Lymphoma Treatment Market Share by

Type (2015-2020)

Table 80. Central & South America Indolent Lymphoma Treatment Market Size by

Application (2015-2020) (Million US\$)

Table 81. Central & South America Indolent Lymphoma Treatment Market Share by

Application (2015-2020)

Table 82. Altor BioScience Corporation Company Details

Table 83. Altor BioScience Corporation Business Overview

Table 84. Altor BioScience Corporation Product

Table 85. Altor BioScience Corporation Revenue in Indolent Lymphoma Treatment

Business (2015-2020) (Million US\$)

Table 86. Altor BioScience Corporation Recent Development

Table 87. Amgen Inc. Company Details

Table 88. Amgen Inc. Business Overview

Table 89. Amgen Inc. Product

Table 90. Amgen Inc. Revenue in Indolent Lymphoma Treatment Business (2015-2020)

(Million US\$)

Table 91. Amgen Inc. Recent Development

Table 92. Astellas Pharma Inc. Company Details

Table 93. Astellas Pharma Inc. Business Overview

Table 94. Astellas Pharma Inc. Product

Table 95. Astellas Pharma Inc. Revenue in Indolent Lymphoma Treatment Business

(2015-2020) (Million US\$)

Table 96. Astellas Pharma Inc. Recent Development

- Table 97. Bayer AG Company Details
- Table 98. Bayer AG Business Overview
- Table 99. Bayer AG Product
- Table 100. Bayer AG Revenue in Indolent Lymphoma Treatment Business (2015-2020) (Million US\$)
- Table 101. Bayer AG Recent Development
- Table 102. Boehringer Ingelheim GmbH Company Details
- Table 103. Boehringer Ingelheim GmbH Business Overview
- Table 104. Boehringer Ingelheim GmbH Product
- Table 105. Boehringer Ingelheim GmbH Revenue in Indolent Lymphoma Treatment Business (2015-2020) (Million US\$)
- Table 106. Boehringer Ingelheim GmbH Recent Development
- Table 107. Bristol-Myers Squibb Company Company Details
- Table 108. Bristol-Myers Squibb Company Business Overview
- Table 109. Bristol-Myers Squibb Company Product
- Table 110. Bristol-Myers Squibb Company Revenue in Indolent Lymphoma Treatment Business (2015-2020) (Million US\$)
- Table 111. Bristol-Myers Squibb Company Recent Development
- Table 112. Celgene Corporation Company Details
- Table 113. Celgene Corporation Business Overview
- Table 114. Celgene Corporation Product
- Table 115. Celgene Corporation Revenue in Indolent Lymphoma Treatment Business (2015-2020) (Million US\$)
- Table 116. Celgene Corporation Recent Development
- Table 117. Eli Lilly and Company Business Overview
- Table 118. Eli Lilly and Company Product
- Table 119. Eli Lilly and Company Company Details
- Table 120. Eli Lilly and Company Revenue in Indolent Lymphoma Treatment Business (2015-2020) (Million US\$)
- Table 121. Eli Lilly and Company Recent Development
- Table 122. F. Hoffmann-La Roche Ltd. Company Details
- Table 123. F. Hoffmann-La Roche Ltd. Business Overview
- Table 124. F. Hoffmann-La Roche Ltd. Product
- Table 125. F. Hoffmann-La Roche Ltd. Revenue in Indolent Lymphoma Treatment Business (2015-2020) (Million US\$)
- Table 126. F. Hoffmann-La Roche Ltd. Recent Development
- Table 127. Gilead Sciences, Inc. Company Details
- Table 128. Gilead Sciences, Inc. Business Overview
- Table 129. Gilead Sciences, Inc. Product

Table 130. Gilead Sciences, Inc. Revenue in Indolent Lymphoma Treatment Business (2015-2020) (Million US\$)

Table 131. Gilead Sciences, Inc. Recent Development

Table 132. Incyte Corporation Company Details

Table 133. Incyte Corporation Business Overview

Table 134. Incyte Corporation Product

Table 135. Incyte Corporation Revenue in Indolent Lymphoma Treatment Business (2015-2020) (Million US\$)

Table 136. Incyte Corporation Recent Development

Table 137. Infinity Pharmaceuticals, Inc. Company Details

Table 138. Infinity Pharmaceuticals, Inc. Business Overview

Table 139. Infinity Pharmaceuticals, Inc. Product

Table 140. Infinity Pharmaceuticals, Inc. Revenue in Indolent Lymphoma Treatment Business (2015-2020) (Million US\$)

Table 141. Infinity Pharmaceuticals, Inc. Recent Development

Table 142. Juno Therapeutics Inc. Company Details

Table 143. Juno Therapeutics Inc. Business Overview

Table 144. Juno Therapeutics Inc. Product

Table 145. Juno Therapeutics Inc. Revenue in Indolent Lymphoma Treatment Business (2015-2020) (Million US\$)

Table 146. Juno Therapeutics Inc. Recent Development

Table 147. MedImmune, LLC Company Details

Table 148. MedImmune, LLC Business Overview

Table 149. MedImmune, LLC Product

Table 150. MedImmune, LLC Revenue in Indolent Lymphoma Treatment Business (2015-2020) (Million US\$)

Table 151. MedImmune, LLC Recent Development

Table 152. Research Programs/Design for This Report

Table 153. Key Data Information from Secondary Sources

Table 154. Key Data Information from Primary Sources



## List Of Figures

### LIST OF FIGURES

- Figure 1. Global Indolent Lymphoma Treatment Market Share by Type: 2020 VS 2026
- Figure 2. BI-836826 Features
- Figure 3. ALT-803 Features
- Figure 4. BMS-986016 Features
- Figure 5. CC-122 Features
- Figure 6. Others Features
- Figure 7. Global Indolent Lymphoma Treatment Market Share by Application: 2020 VS 2026
- Figure 8. Hospital Case Studies
- Figure 9. Clinic Case Studies
- Figure 10. Others Case Studies
- Figure 11. Indolent Lymphoma Treatment Report Years Considered
- Figure 12. Global Indolent Lymphoma Treatment Market Size YoY Growth 2015-2026 (US\$ Million)
- Figure 13. Global Indolent Lymphoma Treatment Market Share by Regions: 2020 VS 2026
- Figure 14. Global Indolent Lymphoma Treatment Market Share by Regions (2021-2026)
- Figure 15. Porter's Five Forces Analysis
- Figure 16. Global Indolent Lymphoma Treatment Market Share by Players in 2019
- Figure 17. Global Top Indolent Lymphoma Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Indolent Lymphoma Treatment as of 2019)
- Figure 18. The Top 10 and 5 Players Market Share by Indolent Lymphoma Treatment Revenue in 2019
- Figure 19. North America Indolent Lymphoma Treatment Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 20. Europe Indolent Lymphoma Treatment Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 21. China Indolent Lymphoma Treatment Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 22. Japan Indolent Lymphoma Treatment Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 23. Southeast Asia Indolent Lymphoma Treatment Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 24. India Indolent Lymphoma Treatment Market Size YoY Growth (2015-2020)

(Million US\$)

Figure 25. Central & South America Indolent Lymphoma Treatment Market Size YoY Growth (2015-2020) (Million US\$)

Figure 26. Altor BioScience Corporation Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 27. Altor BioScience Corporation Revenue Growth Rate in Indolent Lymphoma Treatment Business (2015-2020)

Figure 28. Amgen Inc. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 29. Amgen Inc. Revenue Growth Rate in Indolent Lymphoma Treatment Business (2015-2020)

Figure 30. Astellas Pharma Inc. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 31. Astellas Pharma Inc. Revenue Growth Rate in Indolent Lymphoma Treatment Business (2015-2020)

Figure 32. Bayer AG Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 33. Bayer AG Revenue Growth Rate in Indolent Lymphoma Treatment Business (2015-2020)

Figure 34. Boehringer Ingelheim GmbH Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 35. Boehringer Ingelheim GmbH Revenue Growth Rate in Indolent Lymphoma Treatment Business (2015-2020)

Figure 36. Bristol-Myers Squibb Company Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 37. Bristol-Myers Squibb Company Revenue Growth Rate in Indolent Lymphoma Treatment Business (2015-2020)

Figure 38. Celgene Corporation Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 39. Celgene Corporation Revenue Growth Rate in Indolent Lymphoma Treatment Business (2015-2020)

Figure 40. Eli Lilly and Company Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 41. Eli Lilly and Company Revenue Growth Rate in Indolent Lymphoma Treatment Business (2015-2020)

Figure 42. F. Hoffmann-La Roche Ltd. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 43. F. Hoffmann-La Roche Ltd. Revenue Growth Rate in Indolent Lymphoma Treatment Business (2015-2020)

Figure 44. Gilead Sciences, Inc. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 45. Gilead Sciences, Inc. Revenue Growth Rate in Indolent Lymphoma Treatment Business (2015-2020)

Figure 46. Incyte Corporation Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 47. Incyte Corporation Revenue Growth Rate in Indolent Lymphoma Treatment Business (2015-2020)

Figure 48. Infinity Pharmaceuticals, Inc. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 49. Infinity Pharmaceuticals, Inc. Revenue Growth Rate in Indolent Lymphoma Treatment Business (2015-2020)

Figure 50. Juno Therapeutics Inc. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 51. Juno Therapeutics Inc. Revenue Growth Rate in Indolent Lymphoma Treatment Business (2015-2020)

Figure 52. MedImmune, LLC Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 53. MedImmune, LLC Revenue Growth Rate in Indolent Lymphoma Treatment Business (2015-2020)

Figure 54. Bottom-up and Top-down Approaches for This Report

Figure 55. Data Triangulation

Figure 56. Key Executives Interviewed

## I would like to order

Product name: COVID-19 Impact on Global Indolent Lymphoma Treatment Market Size, Status and Forecast 2020-2026

Product link: <https://marketpublishers.com/r/C919D0118CE5EN.html>

Price: US\$ 3,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C919D0118CE5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

